W. Michael Flanagan insider trades: Atrium Therapeutics (RNA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where W. reports to the SEC
Open-market buys and sales
13 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 21, 2026 | RNA | ↓ Sell10b5-1 | 6,534 | $72.45 | $473K | Direct | Jan 23, 2026 (2d) |
| Sep 11, 2025 | RNA | ↓ Sell | 20,000 | $38.94 | $779K | Direct | Sep 12, 2025 (1d) |
| Jun 11, 2025 | RNA | ↓ Sell | 20,000 | $32.88 | $658K | Direct | Jun 12, 2025 (1d) |
| Mar 20, 2025 | RNA | ↓ Sell10b5-1 | 11,780 | $31.06 | $366K | Direct | Mar 21, 2025 (1d) |
| Mar 11, 2025 | RNA | ↓ Sell | 20,000 | $30.13 | $603K | Direct | Mar 12, 2025 (1d) |
| Jan 21, 2025 | RNA | ↓ Sell10b5-1 | 5,672 | $28.60 | $162K | Direct | Jan 23, 2025 (2d) |
| Dec 18, 2024 | RNA | ↓ Sell10b5-1 | 12,742 | $32.66 | $416K | Direct | Dec 19, 2024 (1d) |
| Dec 11, 2024 | RNA | ↓ Sell | 24,000 | $35.77 | $858K | Direct | Dec 13, 2024 (2d) |
| Oct 1, 2024 | RNA | ↓ Sell | 62,500 | $47.62 | $3.0M | Direct | Oct 3, 2024 (2d) |
| Sep 23, 2024 | RNA | ↓ Sell10b5-1 | 25,000 | $43.95 | $1.1M | Direct | Sep 23, 2024 (0d) |
| Sep 11, 2024 | RNA | ↓ Sell | 111,394 | $40.40 | $4.5M | Direct | Sep 13, 2024 (2d) |
| Jun 18, 2024 | RNA | ↓ Sell10b5-1 | 10,106 | $39.13 | $395K | Direct | Jun 20, 2024 (2d) |
| Jan 22, 2024 | RNA | ↓ Sell10b5-1 | 4,129 | $10.13 | $42K | Direct | Jan 23, 2024 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RNA insiders
Open-market trades in the last 12 months
About W. Michael Flanagan's insider trades
W. Michael Flanagan is an insider at Atrium Therapeutics (RNA). Since Jan 22, 2024, W. has reported no open-market purchases and 13 sales worth $13.3M on SEC Form 4. In the last 12 months: 1 sale ($473K).
7 sales (22% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (10 filings), option exercises (6 filings), shares withheld for taxes (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RNA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.